RedHill Biopharma Ltd. Provides Update On Pk Program In Support Of Ongoing Rhb-104 Phase 3 Crohn's Study
Published: Jan 06, 2014
TEL-AVIV, Israel, Jan. 6, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE: RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today reported preliminary positive results from a Phase I study with RHB-104, a proprietary combination antibiotic oral capsule formulation for the treatment of Crohn's disease, currently undergoing a Phase III study in the U.S., with additional clinical sites planned in Canada and Israel (the MAP US study).
Help employers find you! Check out all the jobs and post your resume.